| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-04-13 |
| タイトル |
|
|
タイトル |
Current status of immunotherapy for sarcomas |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00050497 |
|
ID登録タイプ |
JaLC |
| 著者 |
Miwa, Shinji
Nishida, Hideji
Tsuchiya, Hiroyuki
|
| 著者別表示 |
三輪, 真嗣
西田, 英司
土屋, 弘行
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学医薬保健研究域医学系 |
| 書誌情報 |
Immunotherapy
巻 9,
号 16,
p. 1331-1338,
発行日 2017-11-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1750-743X |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12344283 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.2217/imt-2017-0101 |
| 出版者 |
|
|
出版者 |
Future Medicine |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Although the development of anticancer drugs has improved the outcomes of bone and soft tissue sarcomas, the clinical outcome of patients with relapsed sarcomas remains unsatisfactory due to therapeutic toxicities and resistance to anticancer drugs. Therefore, novel therapeutic modalities are needed to improve the outcome of patients with bone and soft tissue sarcomas. Dendritic cells present tumor antigens and stimulate immune responses, and immune cells, such as cytotoxic T lymphocytes, kill tumor cells by recognizing tumor antigens. However, immune-suppressive conditions by immune regulator PD-1, CTLA-4 and regulatory T cells help tumor growth and progression. In this report, current immunotherapies including cellular immunotherapy and checkpoint inhibitors are introduced, and the advantages and disadvantages of the treatments are discussed. © 2017 2017 Future Medicine Ltd. |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Embargo Period 12 months |
| 権利 |
|
|
権利情報 |
Copyright © Future Medicine |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
ME-PR-MIWA-S-1331.pdf (164.5 kB)
.png)
